A clearance mechanism involving microglia has been known to relieve neurons of toxic protein aggregates such as those associated with Alzheimer’s disease and Parkinson’s disease. Unfortunately, this ...

For years, researchers have watched the tiny power plants inside brain cells falter in Parkinson’s disease and wondered what came first. Did those damaged mitochondria trigger the illness, or did they ...

Gladstone's Ken Nakamura (right) led a study that strengthens the links between energy breakdown in cells and the onset of Parkinson’s, potentially illuminating new paths for treatment. Here, Nakamura ...

The brain contains many cell types, from the prominent neurons to the lesser-known microglia. The latter are integral to the brain's immune system and play a crucial role as the brain's cleanup crew.

For decades, scientists have known that mitochondria, which produce energy inside our cells, malfunction in Parkinson's disease. But a critical question remained: do the failing mitochondria cause ...

A new study led by Rice University's Pernilla Wittung-Stafshede has revealed that protein clumps, or plaques that clog the brain, associated with Parkinson's disease are not merely waste; they can ...

This recent study highlights the neuroprotective potential of TFE3, a transcription factor that plays a pivotal role in counteracting key pathological mechanisms associated with Parkinson's disease ...

Neurodegenerative diseases, such as Alzheimer's disease and dementia, are medical conditions that entail the progressive loss of neurons and a decline in brain function. Past studies have found a link ...

Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to $2.2bn for Arrowhead Pharmaceuticals’ preclinical candidate.

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and ATLANTA and NEW ...